Future perspectives in melanoma research. Meeting report from the "Melanoma Research: A bridge Naples-USA. Naples, December 6th-7 th2010"

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Ascierto, Paolo A ^a   De Maio, Eleonora ^a   Bertuzzi, Stefano ^b   Palmieri, Giuseppe ^c   Halaban, Ruth ^d   Hendrix, Mary ^e   Kashani sabet, Mohamed ^f   Ferrone, Soldano ^g   Wang, Ena ^b   Cochran, Alistair ^h   Rivoltini, Licia ⁱ   Lee, Peter P ^j   Fox, Bernard A ^k,l   Kirkwood, John M ^g   Ullmann, Claudio D ^m   Lehmann, Frederic F ⁿ   Sznol, Mario ^o   Schwartzentruber, Douglas J ^p   Maio, Michele ^q   Flaherty, Keith ^r   Galon, Jerome ^s   Ribas, Antoni ^h   Yang, James ^b   Stroncek, David F ^b   Mozzillo, Nicola ^a   Marincola, Franco M ^b   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CNR   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k EARLE A CHILES RESEARCH INSTITUTE   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^o YALE CANCER CENTER   (United States)

^p INDIANA UNIVERSITY HEALTH   (United States)

^q UNIVERSITY HOSPITAL OF SIENA   (Italy)

^r MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^s CENTRE DE RECHERCHE DES CORDELIERS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AFLIBERCEPT; ALPHA INTERFERON; B RAF KINASE INHIBITOR; BEVACIZUMAB; CISPLATIN; CYCLOPAMINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DASATINIB; GAMMA SECRETASE INHIBITOR; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MELANOMA VACCINE; MK 2206; NILOTINIB; PACLITAXEL; PEPTIDE VACCINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PLX 4032; PROTEIN KINASE B INHIBITOR; RO 4929097; SELUMETINIB; TEMOZOLOMIDE; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; TUMOR MARKER;

ARTHRALGIA; BASAL CELL CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; DIARRHEA; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; INTERNATIONAL COOPERATION; MELANOMA; MONOTHERAPY; NONHUMAN; PHOTOSENSITIVITY; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSLATIONAL RESEARCH; UNITED STATES; UNSPECIFIED SIDE EFFECT; ANIMAL; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; ITALY; METABOLISM; MOUSE; RESEARCH; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; ITALY; MELANOMA; MICE; RESEARCH; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79953098794     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-32     Document Type: Review

References (28)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-23. 10.1056/NEJMoa1003466, 20525992.
2. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-19. 10.1056/NEJMoa1002011, 20818844.
3. Lane J, Bertuzzi S. Measuring the Results of Science Investments. Science 2011, 331:678-80. 10.1126/science.1201865, 21310987.
4. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Allen RE, Singer MI, Leong SPL, Ljung B-M, Sagebiel RW, Kashani-Sabet M. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005, 102:6092-7. 10.1073/pnas.0501564102, 1087936, 15833814.
5. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR, Sagebiel RW. A multi-marker assay to distinguish benign nevi from malignant melanomas. Proc Natl Acad Sci USA 2009, 106:6268-72. 10.1073/pnas.0901185106, 2662963, 19332774.
6. Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SPL, Miller JR, Sagebiel RW, Kashani-Sabet M. Prognostic significance of NCOA3 overexpression in primary cutaneous melanoma. J Clin Oncol 2006, 24:4565-9. 10.1200/JCO.2006.07.3833, 17008696.
7. Kashani-Sabet M, Venna S, Rangel J, Nosrati M, Sucker A, Egberts F, Baehner FL, Simko J, Leong SPL, Haqq C, Hauschild A, Schadendorf A, Miller JR, Sagebiel RW. A multi-marker prognostic assay for melanoma. Clin Cancer Res 2009, 15:6987-92. 10.1158/1078-0432.CCR-09-1777, 2784204, 19887476.
8. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-53. 10.1200/JCO.2006.08.5829, 17577033.
9. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176. 10.1371/journal.pmed.0040176, 1865558, 17488182.
10. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009, 106:9010-5. 10.1073/pnas.0901329106, 2690021, 19451644.
11. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009, 27:38-44. 10.1200/JCO.2008.17.1777, 19047287.
12. Van Den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-93. 10.1016/S0952-7915(97)80050-7, 9368778.
13. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003, 39:70-7. 10.1016/S0959-8049(02)00479-3, 12504661.
14. Kruit WH, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Brichard V, Spatz A, Eggermont A, Keilholz U, Lehmann F. Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group [abstract]. Perspectives in Melanoma 2009, 0-0001.
15. Spatz A, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Louahed J, Peeters O, Lejeune D, Brichard VG, Eggermont A, Keilholz U, Lehmann F. MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI) clinical activity in metastatic melanoma is associated with predictive biomarkers present in the tumor prior to immunization [abstract]. Canadian Melanoma Conference 2010, http://www.buksa.com/melanoma/docs/2010-FinalProgram.pdf
16. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Esteban E, Malinowski W, Jassem J, Passlick B, Lopez Brea M, Debruyne C. Phase II randomized study of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC): 44 month follow-up, humoral and cellular immune response data [abstract]. 2008, 148O. ESMO-IASLC Congress.
17. Louahed J, Lehmann F, Ulloa-Montoya F, Gruselle O, Dizier B, Vansteenkiste J, Kruit W, Brichard V. Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment [abstract]. Molecular Cancer Therapeutics 2009, 8(12 supplements):1. 2775557, 19139107.
18. Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 2009, 27:18s.
19. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010, 8:38. 10.1186/1479-5876-8-38, 2873374, 20406483.
20. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-66.
21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-4. 10.1126/science.1129139, 17008531.
22. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathological-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol
23. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007, 67:1883-6. 10.1158/0008-5472.CAN-06-4806, 17332313.
24. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-22. 10.1016/j.coi.2010.02.006, 20207124.
25. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-40. 10.1053/j.gastro.2009.10.057, 19909745.
26. Pages F, Kirilovsky A, Mlecnik B, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman W-H, Galon J. The in situ cytotoxic and memory T cells predict outcome in early-stage colorectal cancer patients. J Clin Oncol 2009, 27:5944-51. 10.1200/JCO.2008.19.6147, 19858404.
27. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-10. 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5, 8608507.
28. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-102.